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Abstract 
 Backgrounds: Oral mucositis is a frequent adverse side effect of 
cancer chemotherapy which is associated with intense oral pain. However, it 
impairs the quality of life of these patients. Low Level Laser Therapy 
(LLLT) has been increasingly used in recent years, mostly to accelerate 
wound healing and to reduce pain. In cancer patients, LLLT has been shown 
to reduce the incidence and severity of oral mucositis. Objectives: The aim 
of this study is to evaluate the effect of low level laser therapy in the 
management of chemotherapy induced oral mucositis. Patients and 
Methods:  The study design used was a randomized clinical trial. A total of 
67 cancer patients were eligible to participate in the study. Thus, they were 
divided randomly into two groups: group 1 irradiated with prophylactic or 
active laser therapy (AlGalnAs  laser diode device with a wave length of 
940±15nm, 0.3mW, and a probe emitting dose of  4.2 J/cm²) and group 2 
received inactive  or sham laser therapy (power output equal to zero). 
However, for the ethical purpose, once the patients developed ulcerative 
mucositis, they are irradiated with active laser therapy. The oral assessment 
was performed daily starting from the first day of the chemotherapy by 
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applying WHO grading system. After 24 hours, the assessment of associated 
oral pain was carried out every two days with visual analog scale before laser 
application. Consequently, the associations between variables were analyzed 
statistically using SPSS version 20. Results: All the patients were presented 
with some grade of oral mucositis. In the active or prophylactic laser group, 
the severity of oral mucositis was lower than the inactive or therapeutic laser 
group. Moreover, the incidence of grade 3 and grade 4 were less observed in 
the active or prophylactic laser groups than the sham or therapeutic laser 
groups. In addition, the mean time of healing was significantly lower in the 
prophylactic laser group than in the therapeutic laser groups (2.05 + 1.89 
versus 4.5 + 2.4 days, p> 0,004). Prophylactic laser application was 
associated with significant reduction of oral pain in comparison with inactive 
or therapeutic laser therapy (1.18 + 1.09 versus 2.12 + 1.60, p> 0.01). 
Conclusions: Prophylactic laser therapy is effective in reducing the 
incidence of sever oral mucositis and in alleviating associated oral pain. 
 
Keywords: Low level laser Therapy, oral mucositis, chemotherapy, cancer 
patient 
 
Introduction 
 Despite considerable improvement in the medical management of 
cancer patients in recent years, significant complication often accompanies 
the potential benefits of the treatment. Chemotherapy induced oral mucositis 
is a frequent oral complications achieved in patients which receives highly 
mucotoxic drugs (Arora et al., 2008; Sonis, 2009; Ramírez-Amador et al., 
2010; Freitas et al., 2014 ) 
 Oral mucositis is associated with intense pain which limits patient’s 
ability to eat and drink normal foods (Silverman, 2007). Severe and wide 
spread ulcerated mucositis in these group of medically compromised patients 
both physiologically (by the tumour) and literally (by cancer therapy) will 
place them at an increased risk of systemic infection and bleeding 
(Bensadoun, 2012; Sonis, 2009). Consequently, the quality of life of these 
patients will be greatlycompromised (Nes and Posso, 2005; Abramoff et al., 
2008). 
 The literature review revealed that various pharmacological and non-
pharmacological agents have tried to prevent and/or treat oral mucositis. 
Thus, they have made the subject of mucositis to be one of the most 
researched field explored in supportive care in cancer by many researchers 
(Sandoval et al., 2003; Sonis, 2009; Gouvea de Lima et al., 2012). 
 Among the various agents being investigated is the Low Level Laser 
Therapy (LLLT). Laser therapy is a photomedicine procedure proposed to 
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exert beneficial effect in inflammatory conditions like rheumatoid arthritis 
(Bensadoun and Nair, 2012; Ekim et al., 2007). 
 Even though the precise molecular mechanism to explain their 
activity are not clearly evident, however, it has been suggested that LLLT 
will promote wound healing (Volpato et al., 2009). Also, it was observed that 
LLLT will induce biological changes in the epithelial and connective tissues 
through the stimulation of rapid epithelization and regeneration of 
myofibroblast originating from the fibroblast (Chaves et al., 2014 ). 
 Moreover, low power laser have also been reported to exert pain 
relief potential through the modification of nerve conduction via the release 
of endorphins and enkephalines (Jaguar et al., 2007). 
 In addition to these effects, low intensity laser therapy have been 
investigated to prevent and/or treat oral mucositis due to radiotherapy (Arora 
et al., 2008; Gouvea de Lima et al., 2012; Gautam et al., 2012; Carvalho et 
al., 2011); chemotherapy (Nes and Posso, 2005; Abramoff et al., 2008; Cruz 
et al., 2007; Kuhn et al.,2009 ); and in Hematopoetic Stem Cell 
Transplantation (HSCT) (jaguar et al.,2006; Silva et al., 2011). 
 Low level laser therapy has not been studied for cancer patients 
undergoing chemotherapy in our country. Accordingly, we performed a 
double blind randomized study to investigate the clinical effect of low level 
laser therapy in the management of chemotherapy induced mucositis. 
  
Patients and Methods 
The Study Design and Patient Characterization 
 The study was designed as a double blind randomized clinical trial. 
The samplings were carried out in Hiwa Hospital in Sulaimani city (Northern 
east of Iraq) from June 2013 to September 2014. Eligible patients were all 
consecutive cancer patients receiving chemotherapy with the following 
inclusion and exclusion criteria. 
 
Inclusion Criteria 
 Pediatric and young adult patients utilizing intensive mucotoxic 
chemotherapy (single highly mucotoxic drug or combination of two or three 
intensive chemotherapeutic regimen). 
 Patients who stay in hospital for at least 21 days. 
 Patients who agreed to participate in the study. 
 Furthermore, in exclusion criteria, patients were withdrawn from 
participation according to their request or due to loss in follow up, those who 
miss three consecutive day treatments, and those with unstable clinical 
condition. 
 Before conducting the study procedure, the institutional Ethics 
Committee approved the protocol. However, all the procedures were 
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performed in accordance with applicable guidelines of Good Clinical 
Practice and the Declaration of Helsinki. Written informed consent was 
obtained from all patients or their parents before they were enrolled into the 
study procedure. 
 
Prophylactic Laser Application 
 Sixty seven patients met the inclusion and exclusion criteria and they 
were randomly divided into two groups using a block randomization with a 
manual schedule: group A (active laser) and Group B with sham (inactive 
laser). In addition, patients were blinded towards the therapeutic protocol of 
their groups. 
 Laser irradiation were performed with iLase™ (BIOLASE, Inc., 
Irivine, CA92618 USA, with a wave length of 940±15nm, output power 0.3 
mW “Pulse Mode”, continuous infrared AlGalnAs diode) Laser. 
 Patients who participated in the active and passive laser groups were 
irradiated daily for three successive weeks starting from the day of the 
chemotherapy course. At each treatment sessions, ten anatomic sites (the 
right and left hand side of the cheeks, lower and upper labial mucosa, ventral 
and lateral tongue, floor of the mouth and anterior tonsillar pillars) of the oral 
cavity were illuminated for 30s. 
 All the procedure were performed by a single oral medicine 
specialist, after adjustment of the iLase™ device for soft tissue pathology 
(i.e aphthus ulceration mode). Thus, the power output was reduced to 0.3 
mW. This initiated an energy power of 4.2 J/cm² when the probe were held 
at about 7-8mm away from the oral mucosal surfaces 
 In the active or prophylactic group, patients were irradiated with the 
probe emitting dose of 4.2 J/cm². Also, participants in the sham or inactive 
laser group were irradiated with the same, but inactive probes. For ethical 
purpose, once the patients establish a ulcerated mucositis, they are irradiated 
with therapeutic active laser therapy. During irradiation procedure, the 
patients and the therapist wear googles to avoid retinal exposure to laser 
light. Thus, the procedure was carried out in the morning between 9-11pm. 
 Lastly, all the patients underwent hospital stander oral mucositis 
prophylactic measure in the form of Italian solution (A mixture of vit. B 
complex, Folic acid, Normal saline, Mycostatin drop, Hydrocortisone, 
NaHCO3 (Sodium bicarbonate), and Lidocaine ampule). 
  
Clinical Evaluation of Oral Mucositis 
 Patients were assessed for response to laser therapy on a daily basis 
by employing WHO grading system by specialized independent hematologist 
who was blinded regarding the studied groups. The evaluation for the 
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development of ulcerative oral lesion and the time needed for healing were 
also recorded clinically. 
 
Oral Pain Evaluation 
 Subjective evaluation of oral pain was performed every two days 
after receiving chemotherapy using a Visual Analog Scale (VAS), in which 
“0” represent the absence of pain and “10” represent the worst severe pain 
felt by the patient.  Consequently, the Wang-baker Faces pain rating scale 
were used for oral pain in pediatric patients who were not able to rate their 
oral pain in response to laser therapy. 
 
Statistical Analysis 
 All data were analyzed using SPSS (version 20 software) computer 
program. Statistical analysis used in this study included descriptive statistics 
for the evaluation of age, sex, types of tumour, and types of chemotherapy. 
For quantitative variables like pain score and the time of healing, the 
univariate analysis which included t test and Mann-Whitney U test were 
applied. The differences between the studied groups were analyzed by 
adopting Chi-square test and fisher exact test for qualitative variables. The 
strength of association was also   examined using risk ratio. All p values 
were based on 2-sided tests and p <0.05 was considered to be statistically 
significant. 
 
Results 
 A total of 67 patients were consecutively enrolled in the study 
between June 2013 and September 2014. Patient’s characterization, tumor 
types, and chemotherapy regimen are listed in Table 1. The majority of the 
participants were male and most of the patients were diagnosed with 
hematological malignancies. The most frequent types of chemotherapy 
regimen was Methotrexate based regimen in the sham laser group, while  
Etoposide based regimen was most popular in the active laser group of 
patients. 
Table 1: General characteristics of studied patients 
Characteristics Active Laser 
No. = 34 
Sham Laser 
No. = 33 
Age (year), mean + SD 15.6 + 12.0 14.8 + 7.8 
Sex, No. (%) 
Male 
Female 
 
20 (58.8) 
14 (41.2) 
 
21 (63.6) 
12 (36.4) 
Tumor types, No. (%) 
Hematological tumor 
Solid tumor 
 
19 (55.9) 
15 (44.1) 
 
23 (69.7) 
10 (30.3) 
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AML: Acute Myeloid Leukaemia, ALL: Acute Lymphoblastic Leukaemia, NHL: Non 
Hodgkin's Lymphoma, CT: Chemotherapy, MTX: Methotrexate, 5FU: 5 Flurouracile. 
 
Evaluation of Oral Mucositis 
 All patients in both groups were presented with some grade of oral 
mucositis. Although the daily evaluations of oral mucositis revealed no 
statistically significant difference between the studied groups (Table 2), 
however, the incidence of grade 3 and grade 4 were less observed in the 
active or prophylactic  laser groups than sham or therapeutic laser groups 
(figure 1). Moreover, the risk ratio for developing different grades of oral 
mucositis was considerably increased in sham laser groups than active laser 
groups reaching about RR=2.8 for the occurrence of both grade 3 and grade 
4 oral mucositis (Table 3). 
Tumor subtypes 
ALL 10 (29.4) 12 (36.4) 
AML 10 (29.4) 11 (33.3) 
Ewings sarcoma 4 (11.8) 2 (6.1) 
Neuroblastoma 1 (2.9) 3 (9.1) 
Nasopharyngeal 1 (2.9) 0 (0.0) 
Osteosarcoma 3 (8.8) 1 (3.0) 
NHL 1 (2.9) 1 (3.0) 
Brain tumor 4 (11.8) 3 (9.1) 
Total 34 (100.0) 33 (100.0) 
 
CT regimen 
MTX 7 (20.6) 11 (33.3) 
High dose cytosar 5 (14.7) 3 (9.1) 
Etoposide 9 (26.5) 7 (21.2) 
Irinotecan 3 (8.8) 4 (12.1) 
Cisplantine+5 FU 3 (8.8) 0 (0.0) 
Anthracycline 6 (17.6) 7 (21.2) 
Combined 1 (2.9) 1 (3.0) 
Total 34 (100.0) 33 (100.0) 
 
Days Grade 1 Grade 2 Grade 3 Grade 4 P value X2 
Active Sham Active Sham Active Sham Active Sham 
6 1 0 0 0 0 0 0 0 0.468 6.625 
7 3 4 0 0 0 0 0 0 0.022 16.32 
8 6 16 2 1 0 0 0 0 0.169 1.88 
9 15 21 4 6 0 0 0 0 0.924 0.01 
10 14 8 10 19 2 2 0 0 0.117 4.27 
11 10 4 9 17 5 8 0 0 0.070 5.30 
12 7 4 8 11 4 11 0 0 0.168 3.55 
13 7 8 6 5 2 9 1 4 0.233 4.27 
14 8 8 4 7 3 6 0 2 0.525 2.23 
15 8 5 2 9 1 2 0 2 0.104 6.14 
16 4 4 3 11 0 2 0 0 0.233 2.91 
17 2 9 2 3 0 2 0 0 0.451 1.59 
18 1 10 2 1 0 1 0 0 0.076 5.15 
19 3 7 0 1 0 0 0 0 0.520 0.413 
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Table 2: Daily evaluation of oral mucositis in the studied groups according to WHO scoring 
system 
 
Figure 1: The incidence of oral mucositis throughout the study periods in both groups 
(active laser and sham laser). Note: No significant difference between the percentage of 
grades (1, 2, 3, and 4) in active laser and sham laser, P> 0.05. 
 
Table 3. Estimation of Risk ratio for the development of different grades of oral mucositis 
between sham and active laser groups 
 
 
 
 
 
 
 
Time of Healing Oral Mucositis 
 There was a significant difference between the studied groups. 
Therefore, the mean time of healing in the active laser groups was 2.05±1.89 
day, while for the sham laser groups was 4.5 ±2.4 days (i.e. patients who 
received prophylactic active laser therapy requires less time for healing in 
the established oral mucositis than  patients who received therapeutic sham 
laser therapy as shown in table 4) . 
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Sham laser
WHO Grades Risk Ratio (RR) 
RR (grade 1) Sham/active 1.2 
RR (grade 2) Sham/active 1.8 
RR (grade 3) Sham/active 2.5 
RR (grade 4) Sham/active 5 
RR (grade 3 & 4) Sham/active 2.8 
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Table 4.  Mean time of healing in patients received active laser and shame laser 
 
 
 
 
Pain Score 
 The proportion of patients presented with oral pain remained 
insignificant between the studied groups throughout day 6 and 8. Thus, 
significant differences were observed in the following days (table 5). 
Furthermore, the mean value for pain score were kept minimal between the 
studied groups with statistically significant difference (i.e prophylactic and 
therapeutic application of low level laser therapy were associated with the 
reduction of subjective feeling of oral pain; details are shown in table 6). 
Table 5: Mann-Whitney U for difference in pain score in studied groups 
 
Days of treatment  
Pain score  
Median(range) 
 
P value  
Laser Sham 
Day 6 0 (0 – 3) 0 (0 – 3) - 
Day 8 1.5 (0 – 7) 2 (0 – 7) 0.458 
Day 10 2 (0 – 8)  4 (0 – 7) 0.051 
Day 12 2.5 (0 – 8) 4 (0 – 9)  0.032 
Day 14  0 (0 – 5)  3 (0 – 9)  0.008 
Day 16  0 (0 – 4) 2 (0 – 7)  0.001 
Day 18 0 (0 – 3)  0 (0 – 5) - 
Day 20  0 (0 – 3)  0 (0 – 5) - 
 
Discussion 
 Patients undergoing chemotherapy and radiotherapy for the treatment 
of malignant neoplasm often developed oral mucositis as an adverse side 
effect of their treatment. Indeed, oral mucositis regarded as a major 
debilitating and distressing complication often accompanies bone marrow 
transplantation (Abramoff et al., 2008). 
Table 6: Mean pain score value between the group of active laser and sham laser 
 
 
 
 
 
 Oral mucositis can severely impacts the quality of life of these 
individuals and may necessitate cancer treatment cessation or interruption 
which consequently may results in reduced control of local tumor followed 
by an increased morbidity and mortality. Furthermore, cancer treatment 
discontinuation also increases the cost and duration of the treatment and 
prolongs the time of hospitalization (Nes and Posso, 2005). 
Time of healing (day) 
Mean + SD 
 
 
P value Active laser Sham laser 
2.05 + 1.89 4.5 + 2.4 0.004 
 
Study group  
Average pain score 
Mean + SD 
 
 
P value  
Active laser  1.18 + 1.09 0.010 
Sham laser  2.12 + 1.60 
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 Various pharmacological and non pharmacological agents have tried 
in preventing and treating oral mucositis. Despite some positive outcomes, it 
has not be proven to be completely effective in preventing oral mucositis on 
its own. Till now, there are no single intervention acts on all phases of oral 
mucosotis (Bjordal et al., 2011). 
 Low Level Laser Therapy (LLLT) is a local application of a non-
chromatic. However, narrow-band coherent light source used for the 
phtostimulation of biological tissue is recommended as a treatment options 
for oral mucositis (Abramoff et al., 2008; Bjordal et al., 2011).  
 The concept behind the application of laser therapy in the 
management of oral mucositis is that low power lasers induce anti-
inflammatory action and accelerate wound healing by increasing the 
vascularity and reepithelization. In addition, Lopes et al. (2009) showed that  
low power laser appears to decease the severity of oral mucositis, at least in 
part, by reducing the  COX-2 levels which inturn affect the pathophsiology 
of oral mucositis (Sonis et al., 2004). 
 Moreover, recent publication from the Multinational Association for 
Supportive Care in Cancer (MASCC) and the International Society of Oral 
Oncology (ISOO), recommended the administration of LLLT in patients 
receiving HSCT, conditioned with high dose chemotherapy with or without 
total body irradiation (Lalla et al., 2014; Oberio et al., 2014). 
 From this point of view, the present study aimed to evaluate the 
impact of LLLT in the management of chemotherapy induced oral mucositis. 
For this purpose, we conduct a prospective randomized clinical trial in 67 
cancer patients receiving intensive mucotoxic drugs at high risk of 
developing oral mucositis. 
 Our data showed no statistically significant difference between the 
studied groups in terms of the incidence of oral mucositis. Subsequently, the 
active or the prophylactic laser group presented less sever mucositis (grade 3 
and grade 4) than the sham or curative laser group. 
 This finding is fairly consistent with the outcomes of other 
investigators and confirms the advantages of using phototherapy in 
controlling signs and symptoms of oral mucositis in patients undergoing 
cancer chemotherapy (Freitas  et al., 2014; Abramoff et al., 2008; Arbabi-
Kalati et al., 2013) or patients receiving radiotherapy (Carvalho et al., 2011; 
Arora et al., 2008). 
 Similarly, Cown et al. (1997) and jaguar et al. (2007) also found a 
reduction in the progression of sever mucositis using laser illuminations in 
patients who are receiving conditioning regimen for HSCT. 
 In contrast, Gouvea de Lima et al. (2012) revealed that LLLT was not 
effective in reducing the incidence of sever grades of oral mucositis (grade 3 
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or 4) in head and neck cancer patients undergoing concurrent 
chemoradiotherapy. 
 In this present work and for ethical reasons, once the patients 
presented with ulcerated mucositis, they underwent curative laser therapy. 
Although the reason is not entirely understood, curative laser application 
seems to be less successful than prophylactic laser administration. This 
might explain the high risk ratio for developing sever ulcerative mucositis 
(grade 3 and grade 4) in the curative (sham) laser group than prophylactic 
(active) laser group in the present work. 
 In addition, other researchers also confirmed the superiority of 
prophylactic laser application than therapeutic methods (Carvalho et al., 
2011; Arora et al., 2008). Furthermore, in their meta analysis, Oberio et al. 
(2014) demonstrated that local application of laser therapy will reduce the 
overall risk of sever mucositis  and other measures of mucositis severity 
including the duration of sever mucositis and related oral pain. 
 Contrary to our results, Cruz et al. (2007) did not find any evidence 
on the benefit of the preventive use of low level laser therapy in children and 
adolescents with cancer that are treated with chemotherapy. However, one 
plausible cause for the conflicting results may be due to the involvement of 
children and adults with cancer in the current study, and the patients were 
evaluated on a daily basis. Cruz et al. (2007) carried out their evaluation 
weekly on day 1, 8, and 15 after chemotherapy. So, overestimation may be 
noticed by the authors or the authors may also point to the possibility of a 
protective effect of the rigorous oral hygiene carried out in all the 
participants previously and during the study preparation. 
 The time of healing and the duration of sever mucositis was 
significantly lower in the active (prophylactic) laser group than 
sham(curative) laser group, which showed agreement with the previous 
reports declared by Oberio et al., 2014; Volpato et al., 2009; and Bensadoun 
and Nair, 2012. 
 From the patient’s perspective, subjective feeling of pain is the most 
distressing side effect of oral mucositis. This is because it interferes with the 
ability to eat, drink, swallow, and speak. Also, it results in an increase in the 
amount of analgesic administration and parenteral nutrition. Our observation 
demonstrates a statistically significant reduction in the time of oral pain in 
the active laser group in comparison to the curative or sham laser group. 
Interestingly, the pain score in the sham laser group was also reduced and did 
not exceed 2.12 + 1.60. Moreover, the mean pain score was reduced in the 
active laser group than in the sham laser group. 
 The inference of the study results clearly indicate that the reduction 
of oral pain experience was the most remarkable effect of LLL therapy 
reported by our patients. Therefore, this fact was accepted by many 
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investigators in the literature (Bensadoun et al., 1999; Cown et al., 1997; Nes 
and Posso, 2005; Jaguar et al., 2007; Schubert et al., 2007; Abramoff et al., 
2008; Gautam et al., 2012).  
 However, Gouvea de Lima et al. (2012) and Wong and Wilder- 
Smith (2002) presented different data. The former showed that the oral pain 
between placebo and the treated group with laser device does not differ 
considerably in head and neck cancer patients receiving chemoradiotherapy. 
Furthermore, the latter reported lack of any statistically significant difference 
in pain scores at baseline and weekly, thereafter (except in 1 patient) in 
patients receiving chemotherapy. 
 However, it is often difficult to compare their study results with the 
present study, taking into consideration the difference between radiation 
induced and chemotherapy induced mucositis. In addition, the diverse 
parameters and different laser device applied in their study may address the 
discrepancy of their results with ours.  
 In conclusion, our findings relates well to the emerging LLLT 
evidence in preventing oral mucositis and reducing the severity and potential 
pain related to this conditions. It is also interesting to note that the variety of 
cancer chemotherapies administered by our patients did not seem to seriously 
interfere with the beneficial effects of LLLT. Furthermore, the device was 
well tolerated and no serious incidents or withdrawal due to treatment 
intolerance were reported by our patients. 
 Consequently, low power laser should be target for future trials to 
compare treatment start at different time points before cancer therapy to 
avoid unnecessary LLLT exposure. 
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